Autonomize ships Context AI so healthcare agents share one governed knowledge layer

Autonomize said Thursday that Autonomize Context AI is generally available — a shared context foundation that turns clinical terminology, policies, and institutional rules into living, auditable intelligence healthcare AI agents can reuse across workflows.

Healthcare agents keep re-learning the same policy binder and still disagree with each other. Context AI’s bet is ordinary and important: define the concepts and plan rules once, keep protected health information and proprietary logic in a customer-owned layer, and make every prior-authorization or claims agent cite the same governed source instead of freestyling from a chat model.

On Thursday, 1 October 2026, Autonomize announced that Autonomize Context AI is generally available. Generally available means a customer can get the product now, not only in a closed trial. GlobeNewswire carries the release. The page stamps October 01, 2026, 09:00 ET, which is 9:00 a.m. Eastern. The dateline is Austin, Texas. The source line is Autonomize AI. Autonomize calls the product a shared intelligence foundation that turns scattered company knowledge into living context a healthcare AI agent can understand and apply. An agent, here, is software that takes a next step in a workflow, such as routing a request or drafting a reason for a decision. The release says the product sits on data platforms a customer already runs. It does not name those platforms. Those lines are Autonomize’s.

What the company says the product is for. An organization defines clinical terminology, operating rules, relationships, and in-house expertise once, then governs that package and reuses it across agents, workflows, and departments. Clinical terminology is the shared vocabulary for a condition, a drug, or a procedure. The release says the result is more reliable, more efficient, and easier to scale, on a connected base that keeps a record and gets more capable with use. Without that shared base, Autonomize says, agents on separate systems keep fetching the same facts, reconciling words that do not match, reading policies that do not connect, and rebuilding logic the organization already wrote. A policy, here, is a rule for what care the plan will pay for. If there is no single source of truth, two agents can apply the same rule differently. Autonomize says that raises cost and delay, adds variation, weakens the trail back to a source, and wears down trust. Those lines are Autonomize’s account of the problem.

The product has two layers, as the release states them. The Context Graph is an industry ontology filled out with licensed material for health plans, hospitals and clinics, life-sciences companies, and biopharmaceutical companies. An ontology is a map of terms and how they relate, so “the same drug” or “the same benefit” means one thing to every agent. Licensed material is content the company says it has the right to include, drawn from healthcare standards, not from one customer’s private files. Enterprise Extensions are the customer-controlled layer on top of that shared map. They hold that organization’s policies, formularies, provider networks, fee schedules, standard operating procedures, usage patterns, and other knowledge it owns. A formulary is the plan’s list of covered drugs and the rules for them. A fee schedule is what the plan pays for a service. A standard operating procedure is the written step-by-step the staff already follows. Autonomize says splitting this knowledge off from the language model, and off from any one agent, lets a customer keep proprietary know-how out of an outside model provider. A language model is the system that writes an answer from a prompt. Proprietary means the customer’s own, not the shared industry map. Those lines are Autonomize’s.

Laksh Krishnamurthy, chief technology officer of Autonomize AI, is quoted in the release. He said the company built the Context Graph as a substrate, not a snapshot, with more than 10 million clinically reviewed concepts drawn from healthcare ontologies and standards. A substrate, in that sentence, is a base other things sit on, meant to keep growing, rather than a one-time export. A concept, here, is one reviewed idea in that map, such as a clinical term and the links around it. Ten million is the company’s count of those concepts. It is not a count of patients, and it is not a count of claims. He said each customer can extend the graph with its own policies, plan rules, and protected health information without changing the shared foundation or mixing proprietary information into it. Protected health information is the health detail a plan or a hospital has to keep private. He said that gives agents the healthcare knowledge and the organizational context they need, while the customer keeps ownership, control, and traceability. Traceability means a later reviewer can see which concept, policy, and source informed a decision. That quotation is his, in the release.

Ganesh Padmanabhan, chief executive and co-founder, is quoted on the same release. He said healthcare gets better when human expertise and AI learn from each other. He said Context AI lets customers keep ownership of the knowledge, the logic, and the workflows that make their organizations distinct, while every agent they deploy gets a shared, governed understanding of what that knowledge means. He said that is what makes it possible to scale AI in a regulated industry without giving up control or the ability to audit. The release says knowledge is grounded once and reused, which cuts unnecessary calls to a model and improves consistency. A model call is one request sent to the language model. Fewer repeat calls is the company’s efficiency claim. It does not print a dollar saving. The same page says every agent-supported decision, from routing a prior authorization to a payment-integrity review to a coverage determination, can be traced to the concepts, policies, evidence, and sources behind it. A prior authorization is the plan’s check before it will pay for a treatment. A coverage determination is the decision about whether that treatment is covered. Because the customer’s knowledge stays in the customer-controlled layer, and because models are treated as interchangeable parts, Autonomize says an organization can try, manage, and replace a large or a small language model as the market changes, without rebuilding its institutional intelligence or giving up ownership of it. Those lines are the release.

Autonomize says Context AI is already powering agents in day-to-day healthcare operations. On utilization management, it says the product coordinates prior authorization, concurrent review, and retrospective review across the course of care. Concurrent review is a check while the person is still receiving care. Retrospective review is a check after the care. Requests are routed by type, by urgency, and by line of business, which is the book of coverage the plan runs. They are checked against that organization’s own medical-policy library, against that payer’s coverage decisions, and against state rules in effect on the date of service. A payer is the plan or insurer that pays the claim. On benefit configuration, Autonomize says the product turns evidence-of-coverage documents and plan documents into structured coverage rules, including copays, coinsurance, limits, and exclusions. An evidence of coverage is the document that says what the plan pays. A copay is a flat fee. Coinsurance is a percentage of the bill. Later agents can apply those rules without reading the original document again each time. On payment integrity, which is the work of checking that a bill matches the care, Autonomize says the product compares medication-administration records with the itemized bill to find mismatches. It says those reviews are grounded in National Correct Coding Initiative procedure-to-procedure edits, medically unlikely edits, HCPCS billing units, and single-dose vial wastage rules. The National Correct Coding Initiative is Medicare’s set of rules for which procedure codes may be billed together. A medically unlikely edit flags a quantity too high to believe for one patient on one day. HCPCS billing units are the codes and counts used when a drug or a supply is billed. Single-dose vial wastage is the rule for the unused drug left in a vial opened for one patient. Those lines are Autonomize’s. The release does not name a hospital or a health plan running these workflows.

Two more workflows, on the same list. For claims, appeals, and grievances, Autonomize says the product decides claims against the customer’s own standard operating procedures. A grievance is a complaint about the plan, as distinct from an appeal of a coverage decision. For an appeal or a grievance, it says the product classifies the request, pulls the policy version that governed the original decision, and drafts a rationale that points back to the source. For pharmacy and pharmacy-benefit management, it says the product lines up National Drug Codes across the form that was submitted, the form that was dispensed, and the form that was billed. A National Drug Code is the identifier on a drug package. A pharmacy benefit manager runs a health plan’s drug benefit. The release says the product checks a prior-authorization request against formulary tiers, step-therapy rules, and quantity limits. A formulary tier is the level on the drug list that sets what the person pays. Step therapy is the rule that a person tries a preferred drug first. It says the product applies age-based dosing and Medicare Part B drug prices based on average sales price, the benchmark Medicare uses for many drugs given in a clinic. It also says the product reconciles specialty and high-cost drug requests, including GLP-1 medications, against the plan’s own clinical criteria. A GLP-1 drug is a class used for diabetes and for weight loss. Those lines are Autonomize’s. The release does not name a pharmacy benefit manager, and it does not print a count of GLP-1 requests.

The about box describes the company, not a scorecard for Thursday’s product alone. It says the Autonomize Intelligence Platform brings together data, context, agents, and applications for clinical, operational, and administrative work, including utilization management, prior authorization, care management, claims, pharmacy benefits, appeals, payment integrity, quality, and regulatory compliance. It says the platform applies each organization’s own data, policies, knowledge, and decision logic, that specialized agents work beside clinical and operational teams, and that consequential decisions stay under human oversight. Consequential, here, means a decision that matters for a person’s care or for a payment. The same box says Autonomize is trusted by leading U.S. healthcare enterprises and has delivered up to 55 percent faster clinical reviews, 60 percent faster decision turnaround, a lower administrative burden, and 3–5x return within 6–12 months. Up to 55 percent faster means, at the ceiling the company states, a review that took 100 minutes could take 45. It is not a promise that every review hits that mark. Sixty percent faster decision turnaround means, on the same kind of ceiling, a decision that took 10 days could take 4, because 60 percent faster leaves 40 percent of the old time. A 3–5x return means the company says customers got back three to five dollars for each dollar spent, inside six to twelve months. Return, here, is the company’s word for that payback. The about box does not say an outside auditor measured the figures, and it does not say they were measured on Context AI alone. They are Autonomize’s claims for the broader platform. The company homepage prints different platform figures: 80 percent faster case review, 36,000 clinical hours saved a month, a 63 percent cut in turnaround time, and 98 percent of AI-generated information accepted by clinicians. Those homepage lines are not in Thursday’s release, and the release does not tie them to Context AI.

The same about box says Autonomize is a World Economic Forum Technology Pioneer, a top-100 company on the Inc. 5000, and a Modern Healthcare Best Place to Work. The Inc. 5000 is a published list of fast-growing private companies in the United States. Top 100 is the company’s statement of its place on that list. The box names the backers as Valtruis, Asset Management Ventures, Cigna Group Ventures, ATX Venture Partners, and TAU Ventures. Cigna Group Ventures is named there as a backer. The release does not name Cigna, or any other health system, as a customer of Context AI. The release says the product is available today. It points readers to autonomize.ai and to info@autonomize.ai for a working session. It does not print a price. It does not describe a Food and Drug Administration device clearance. Thursday’s news is a software release the company says is generally available.

The picture is a desk graphic of the two layers. The field is coral. On the left, a card labeled Context Graph calls that layer the shared industry ontology and prints more than 10 million clinically reviewed concepts, with labels for terminology, ontologies, and standards. An arrow points to the right-hand card, labeled Enterprise Extensions, the customer-owned layer, with labels for policies, formularies, networks, standard operating procedures, and protected health information. Along the bottom, four labels name workflows from the release: prior authorization, claims, pharmacy, and payment integrity. A line under the cards reads Autonomize Context AI, GlobeNewswire, and October 1, 2026. It is a diagram of the product in the release. It is not a screenshot from a hospital system, and it is not a photograph of a clinic.

In plain terms, Autonomize said on Thursday that Context AI is generally available as a shared base for healthcare agents. One layer is a Context Graph the company says holds more than 10 million clinically reviewed concepts. The other is a customer-owned layer for plan rules, formularies, and private health details, kept off the shared map and off an outside model. The company says the same base already feeds prior authorization, benefit setup, payment integrity, claims and appeals, and pharmacy review, including GLP-1 criteria. The speed and return figures in the about box are the company’s claims for the broader platform. The release does not name a health-system customer for Context AI, does not print a price, and does not describe a device clearance.